Description
The emergence of the COVID-19 pandemic resulting from the spread of the SARS-CoV-2 virus has ignited a massive global research effort for development of COVID-19 vaccines, therapeutics, and tests for viral infections and antibody responses. These time-critical efforts have also put into focus the need for better approaches for immune response analysis in both the human population exposed to the wild virus and in vaccine studies. In addition to population monitoring and vaccine studies, ligand binding assays may be of use in library screens to identify monoclonal antibodies, peptides, and small molecules, that may block infection or lower the infection rate of SARS-CoV-2 virus.
To keep step with these rapidly developing efforts, SARS-CoV-2 spike protein ligand binding assay allows rapid quantification of COVID-19 antibodies in serum that block the interaction of spike protein with its receptor ACE2. This assay allows rapid bioanalysis of antibody-based therapeutics, vaccine leads, and immune response to the virus in the human population